Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclatasvir + Peg-IFN/RBV in HCV Genotype 1/4
NCT01125189Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2010
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of daclatasvir in hepatitis C (HCV), sponsored by Bristol Myers Squibb. Started Jul 2010; status: completed.
02
Drugs
daclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01125189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01125189.